Hospital

Expert Nikhil Palekar, MD, said that although the treatment is far from a cure, it is a vital first step toward other treatments for Alzheimer Disease.

Diagnostic technologies are advancing quickly, which may lead to therapeutics for age-related diseases to safely reduce chronic low-grade inflammation generated by the immune system.

Oncology pharmacy is best learned in real time with real oncologists and real patients.

Clinical pharmacy services became eligible for reimbursement by all health insurance in Germany; however, challenges persist in upscaling and sustaining these services.

The novel treatment may be able to generate new cardiac tissue to create a functional human heart muscle.

Trial shows an improved survival rate at 4 years when treated with the STRIDE regimen in comparison to treatment with sorafenib in patients with unresectable hepatocellular carcinoma.

Lecanemab-irmb is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer disease.

In a study of individuals with Medicare, the incidence of type 2 diabetes was associated with approximately $30,000 to $98,000 excess lifetime medical expenditures.

Pirtobrutinib is a non–covalent (reversible) BTK inhibitor, demonstrating a 73.3% overall response rate with a median follow-up of 19.4 months among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

mRNA-1345 is a vaccine indicated for the prevention of respiratory syncytial virus-associated lower respiratory tract disease and acute respiratory disease.

Nonpharmacologic and nonopioid treatments associated with improvements in pain and/or function that appear comparable to opioid treatments.

Despite recommendations for adults to receive lung cancer screenings, rates have remained low compared with other cancer screening programs.

The safety and efficacy of long-term benzodiazepine use beyond the recommended timeframe is not well understood.

More than half of the patients prescribed oral anticancer agents report persistent moderate-to-severe symptoms, despite receiving counseling on adverse effect management.

To slow the production of MCI and dementia, utilizing more ways of establishing the diagnoses for women can prevent the progression.

If finalized, the regulation would potentially reduce prescription nonadherence and accidental misuse.

Adalimumab-adaz HCF in the 100 mg/mL strength is approved for indications that are no longer covered exclusively for the reference Humira after July 2023.

Pharmacists can use their knowledge and professional judgment to educate patients about when it is appropriate to take these medications and when to avoid them.

By empathizing with patients and creating an environment where patients feel comfortable and open to sharing, pharmacists can increase compliance and adherence.

Pharmacists must find innovative health care solutions to combat the hefty financial burden associated with treating cancer.

Using data from a wide-ranging survey of Medicare enrollees, investigators found that using value weights from participants would have a negative impact on smaller, rural hospitals.

Less than half of respondents would recommend a vaccine against respiratory syncytial virus to a pregnant friend or family member.

Renewed focus on the potential this drug can provide patients is upon us as we continue to strive for greater and better care and treatment for patients throughout US health systems.

Preliminary estimates from the 2022 to 2023 season suggest that the burden of influenza is returning to a pre-pandemic level.

We all have an interest in reducing harm and deaths from opiates and other controlled substances, but we should have evidence-based and patient-centered approaches that do not have unintended consequences on patient health and safety.

Valoctocogene roxaparvovec-rvox (Roctavian; BioMarin) is a one-time gene therapy product administered as a single dose by intravenous infusion for hemophilia A.

The new RSV vaccines are expected to be available in fall 2023.

Researchers noted that the therapy remains risky, owing to the substantial immunosuppressive and cytopenic effects of the trial protocol and the risks that immune-cell manipulation carries.

Until now, studies examining the relationship between testosterone and adverse cardiovascular events in men with hypogonadism were limited and inconsistent.

Despite prior studies showing less brain injury biomarkers in patients with targeted mild hypercapnia, findings from a new trial suggest it does not improve neurological outcomes at 6 months.